PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
503.87 - 512.55
344.79 - 555.45
23.62M / 20.39M (Avg.)
37.30 | 13.67
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-0.50%
Negative net income growth while CRWV stands at 7.67%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
-11.29%
Negative yoy D&A while CRWV is 26.15%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-130.74%
Both reduce yoy usage, with CRWV at -110.52%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-130.74%
Negative yoy usage while CRWV is 112.72%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
79.65%
Well above CRWV's 23.14%. Michael Burry would worry about large intangible write-downs or revaluation gains overshadowing real performance.
-23.78%
Both yoy CFO lines are negative, with CRWV at -510.76%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
52.40%
Some CapEx rise while CRWV is negative at -74.30%. John Neff would see competitor possibly building capacity while we hold back expansions.
No Data
No Data available this quarter, please select a different quarter.
76.62%
Purchases growth of 76.62% while CRWV is zero at 0.00%. Bruce Berkowitz sees a mild difference in portfolio building that might matter for returns.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
We reduce yoy other investing while CRWV is 202.79%. Joel Greenblatt sees a near-term cash advantage unless competitor’s intangible or side bets produce strong returns.
12.06%
We have mild expansions while CRWV is negative at -70.42%. John Neff sees competitor possibly divesting or pausing expansions more aggressively.
No Data
No Data available this quarter, please select a different quarter.
192.22%
Stock issuance far above CRWV's 4.88%. Michael Burry flags a significant dilution risk vs. competitor’s approach unless ROI is very high.
27.34%
Buyback growth of 27.34% while CRWV is zero at 0.00%. Bruce Berkowitz sees a modest per-share advantage that might accumulate if the stock is below intrinsic value.